Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 7/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 5/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7880401 | 0.89 | HCRTR1 (0.42) | HCRTR2HCRTR1ATMATRDHODH | |
| SCHEMBL451554 | 0.88 | HCRTR1 (0.46) | HCRTR2HCRTR1ATMATRCYP46A1 | |
| SCHEMBL438304 | 0.82 | HCRTR2 (0.61) | HCRTR2HCRTR1ATMATR | |
| SCHEMBL439577 | 0.77 | HCRTR1 (0.79) | HCRTR2HCRTR1 | |
| SCHEMBL469126 | 0.76 | HCRTR1 (0.36) | HCRTR2HCRTR1ATRCYP11B1CYP11B2 | |
| SCHEMBL438348 | 0.74 | ATM (0.41) | HCRTR2HCRTR1ATMATRCYP11B1 | |
| SCHEMBL13097147 | 0.73 | CYP2A6 (0.44) | HCRTR2HCRTR1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL19406805 | 0.72 | IRAK4 (0.51) | HCRTR2HCRTR1ATMRAB9ACYP46A1 | |
| SCHEMBL7877771 | 0.72 | HCRTR1 (0.57) | HCRTR2HCRTR1ATRCYP11B1CYP11B2 | |
| SCHEMBL441242 | 0.71 | LRRK2 (0.47) | HCRTR2HCRTR1ATMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438041-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| WO-2010141275-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | HCRTR2 1/4885HCRTR1 2/4885ATM 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.